MedTrace Logo

Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock

NCT06471231 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2024-06-24

No results posted yet for this study

Summary

The aim of the present study is to verify whether the earlier association of vasopressin and norepinephrine, in patients in septic shock, determines variations in terms of use of renal function replacement techniques in the first 7 days of hospitalization in Intensive Care, compared to patients in whom vasopressin is added only when norepinephrine reaches a higher dose.

Conditions

  • Septic Shock
  • Renal Function Replacement

Interventions

DRUG

vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min

when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.

DRUG

vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min

the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP

Sponsors & Collaborators

  • Azienda Usl di Bologna

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2026-05-15
Completion
2026-05-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06471231 on ClinicalTrials.gov